Single-Stranded AAV Vector Synthesis for Strand-Specific Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional AAV vectors face limitations in viral packaging capacity, immunogenicity, slow gene expression, and production inefficiencies, leading to challenges in large-scale, high-purity, and specific strand delivery for therapeutic applications.
Innovation Solution
The production of single-stranded AAV vectors is achieved through cell-free methods using closed-ended DNA with designed gaps or nicks, allowing for controlled synthesis of either plus or minus strands, enhancing purity and strand specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional AAV production from host cells is used, then viral packaging capacity is limited to about 4.5 kb, but cell-free synthesis methods enable increased transgene capacity
Solution Approach 1:
The patent replaces the biological production system (host cells) with a cell-free in vitro synthesis system. This substitution eliminates the constraints of viral packaging capacity that limit conventional AAV production, enabling the synthesis of AAV vectors with larger transgene capacities exceeding the traditional 4.5 kb limitation while maintaining controlled production conditions
Solution Approach 2:
The invention changes the fundamental production parameters by transitioning from in vivo cellular synthesis to in vitro cell-free synthesis. This parameter change allows for the production of AAV vectors with modified characteristics including increased transgene capacity, controlled strand specificity, and enhanced purity without being constrained by natural viral packaging limits
2Manufacturing precision
If conventional AAV production is used, then a random mixture of plus and minus stranded vectors is produced, but cell-free methods enable controlled synthesis of specific strands
Solution Approach 1:
The patent applies local quality control by designing the in vitro synthesis system to produce specifically plus-stranded or minus-stranded AAV vectors according to therapeutic needs. By controlling the synthesis conditions and template design, the method generates homogeneous populations of vectors with uniform strand orientation, eliminating the random mixture problem inherent in conventional production
Solution Approach 2:
The invention implements preliminary action by pre-designing the synthesis templates and reaction conditions to favor the production of the desired strand orientation. The cell-free system is configured beforehand with specific primers, nucleotides, and enzymatic components that direct synthesis toward producing predominantly one strand type, ensuring high strand specificity before the actual vector production occurs
3Manufacturing precision
If conventional AAV production from host cells is used, then contaminants from cells are present, but cell-free methods produce higher purity vectors
Solution Approach 1:
The patent extracts the AAV synthesis process from the host cell environment, removing the source of cellular contaminants. By performing synthesis in a cell-free in vitro system, the method eliminates contamination from cellular proteins, nucleic acids, and other impurities that are inherently present in conventional host cell-based production, resulting in higher purity vector preparations
Solution Approach 2:
The invention uses copying by creating synthetic AAV vectors in a controlled in vitro environment that mimics essential cellular functions without requiring actual cells. The cell-free system replicates the necessary synthesis machinery using purified enzymes and substrates, producing vectors that are free from cellular contaminants while maintaining the required structural and functional characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables high-purity, strand-specific AAV vectors with increased transgene capacity, overcoming limitations of conventional methods by providing efficient and controlled production of therapeutic AAV vectors.
Implementation Method 1
contacting the gapped closed-ended DNA vector with an exonuclease, thereby producing a single stranded AAV vector synthetically
Data Source
AI summary
The present application discloses methods for synthetic production and cell-free synthesis of single stranded adeno-associated virus (AAV) vectors, for delivery and expression of a transgene in host cells. The present invention also relates to an in vitro process for production of closed-ended DNA vectors and corresponding single stranded AAV DNA vector products synthesized from the closed-ended DNA vectors having nicks.